# Cannabigerol Induces ER Stress-Mediated Apoptosis and Ferroptosis in Pancreatic Cancer > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabigerol-pancreatic-cancer-cells-apoptosis-ferroptosis/ > **Published:** 2026-03-24T17:10:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:31-04:00 > **Clinical Summary:** Explore how cannabigerol pancreatic cancer cells trigger apoptosis and ferroptosis via the IRE1α-XBP1 axis, revealing new preclinical insights. --- CED Clinical Relevance  #62Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic CbgCancerPancreatic CancerPreclinicalApoptosis Journal Free radical biology & medicine Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters This study provides the first mechanistic evidence for cannabigerol’s anti-cancer activity specifically in pancreatic cancer cells, one of the most aggressive malignancies with limited treatment options. Understanding CBG’s distinct molecular pathways—particularly its dual induction of apoptosis and ferroptosis—could inform future therapeutic development. Clinical Summary This laboratory study investigated CBG’s effects on human pancreatic cancer cell lines, demonstrating that CBG induces cell death through two distinct mechanisms: apoptosis (programmed cell death) and ferroptosis (iron-dependent cell death). The researchers identified that CBG triggers endoplasmic reticulum stress via the IRE1α-XBP1 pathway, leading to cell cycle arrest and ultimately cancer cell death. While mechanistically compelling, this remains preclinical research conducted on isolated cancer cells in laboratory conditions, with no human clinical data on safety or efficacy. Dr. Caplan’s Take “I find the dual-pathway mechanism intriguing, but we’re still years away from clinical application. Pancreatic cancer patients desperately need better options, but laboratory findings like these require extensive safety studies and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) before we can make any treatment recommendations.” Clinical Perspective 🧠 Clinicians should recognize this as promising preclinical research that adds to our understanding of cannabinoid mechanisms, but should not alter current pancreatic cancer treatment protocols. Patients inquiring about CBG for cancer should understand that laboratory studies do not translate directly to clinical efficacy or safety in humans. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabigerol%20Induces%20Endoplasmic%20Reticulum%20Stress-Mediated%20Apoptosis%20and%20Ferropt...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41871732/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41871732/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabigerol%20Induces%20Endoplasmic%20Reticulum%20Stress-Mediated%20Apoptosis%20and%20Ferropt...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41871732/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41871732/](https://pubmed.ncbi.nlm.nih.gov/41871732/) Table of Contents - [FAQ](#FAQ)[What is cannabigerol (CBG) and how does it differ from other cannabis compounds?](#What_is_cannabigerol_CBG_and_how_does_it_differ_from_other_cannabis_compounds) - [How effective is CBG against pancreatic cancer cells in laboratory studies?](#How_effective_is_CBG_against_pancreatic_cancer_cells_in_laboratory_studies) - [What makes this pancreatic cancer research particularly significant?](#What_makes_this_pancreatic_cancer_research_particularly_significant) - [Are these findings ready for clinical application in cancer patients?](#Are_these_findings_ready_for_clinical_application_in_cancer_patients) - [What are the next steps needed to translate this research into potential treatments?](#What_are_the_next_steps_needed_to_translate_this_research_into_potential_treatments) - [Related](#Related) ## FAQ #### What is cannabigerol (CBG) and how does it differ from other cannabis compounds? Cannabigerol (CBG) is a non-psychoactive phytocannabinoid derived from Cannabis sativa, meaning it does not produce the “high” associated with THC. This study demonstrates that CBG has potent anticancer properties against pancreatic cancer cells, working through unique mechanisms involving endoplasmic reticulum stress and cell death pathways. #### How effective is CBG against pancreatic cancer cells in laboratory studies? CBG showed significant antiproliferative effects against human pancreatic cancer cells by arresting cell growth and inducing two types of programmed cell death: apoptosis and ferroptosis. The compound works through the IRE1α-XBP1 pathway, causing endoplasmic reticulum stress that ultimately kills cancer cells. #### What makes this pancreatic cancer research particularly significant? This is the first study to demonstrate CBG’s therapeutic potential specifically against pancreatic cancer, one of the most aggressive and treatment-resistant cancers. The research reveals novel mechanisms of action that could potentially be exploited for developing new pancreatic cancer treatments. #### Are these findings ready for clinical application in cancer patients? These are preclinical laboratory findings using cancer cell cultures, not human patients. Extensive additional research including animal studies and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) would be required before CBG could be considered as a potential pancreatic cancer treatment in [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). #### What are the next steps needed to translate this research into potential treatments? Future research must include animal studies to evaluate CBG’s safety and efficacy in living organisms, followed by human clinical trials if promising results continue. Researchers also need to determine optimal dosing, [delivery methods](https://cedclinic.com/state-ban-smokable-cannabis-impact-central-texas/), and potential interactions with existing cancer therapies. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Cannabigerol Induces Endoplasmic Reticulum Stress-Mediated Apoptosis and Ferroptosis via the IRE1\u03b1-XBP1 Axis in Human Pancreatic Cancer Cells.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41871732/”, “about”: “free radical biology medicine clinical study”, “isPartOf”: “Free radical biology & medicine”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Almost – CBD and THC did more than just affect ovarian cancer cells in the lab. Researchers …](https://cedclinic.com/preclinical-cancer-research-cannabinoids-cbd-thc-effects/) Explore research on how CBD and THC impact ovarian cancer cells beyond initial expectations. [Read More](https://cedclinic.com/preclinical-cancer-research-cannabinoids-cbd-thc-effects/) [Understanding the Effects of Cannabis on Inflammation – NUG Magazine](https://cedclinic.com/cannabinoid-mechanisms-action-inflammation/) Learn about cannabis's role in modulating inflammation and its therapeutic potential. [Discover Insights](https://cedclinic.com/cannabinoid-mechanisms-action-inflammation/) [Unsung Cannabis Crusader: The Untold Story of Medical Marijuana & Cancer](https://cedclinic.com/cannabis-pharmacology-cancer-research-insights/) Delve into the history and impact of [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) in cancer treatment narratives. [Explore Story](https://cedclinic.com/cannabis-pharmacology-cancer-research-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).